News News Details

港交所迎来小分子创新药第一股--亚盛医药

Date: 2019-11-04
Views: 18

今早,亚盛医药在港交所敲锣上市,成为港交所小分子创新药第一股。



此次亚盛医药在全球发行配售期间实现了超额认购,发售股份定价为每股34.2港元,有效申请认购合共9.16亿股,相较于香港公开发售总数121.8万股而言,实现超额认购约751倍,在目前港交所已上市的创新药公司中处于首位,夺得“认购王”称号。

港交所迎来小分子创新药第一股--亚盛医药亚盛医药董事长杨大俊港交所敲锣



港交所迎来小分子创新药第一股--亚盛医药

                                                                                 倚锋资本董事长朱晋桥与亚盛医药董事长杨大俊


亚盛医药是一家立足中国、面向全球的处于临床阶段的原创新药研发企业,致力于在肿瘤、乙肝及与衰老相关的疾病等治疗领域开发创新药物。公司拥有自主研发的蛋白-蛋白相互作用靶向药物设计平台。亚盛医药研发产品管线主要专注细胞凋亡通路关键蛋白的抑制剂,通过抑制Bcl-2、IAP 或 MDM2-p53 等通路,重启肿瘤细胞的凋亡程序;第二代和第三代的针对癌症治疗中出现的激酶突变体的抑制剂等。


港交所迎来小分子创新药第一股--亚盛医药

                                                                                              倚锋资本与亚盛医药港交所合影



亚盛医药拥有全球最全面的细胞凋亡药物管线。已构建拥有8个1类新药的产品管线,均有望成为同类首创/同类最佳药物。目前在中国、美国及澳大利亚开展了28项I/II期临床试验,研究新药在单一用药或联合疗法方面的潜力。从适应症来看,在中国乃至全球都是大病种领域,或可在任何领域撬动百亿乃至上千亿级市场。


值得一提是,中国生物制药在几日前也宣布成为亚盛医药在港交所IPO的基石投资者中国生物制药是香港上市的最大医药公司之一,也是中国知名医药企业正大天晴的母公司。



我们祝贺亚盛医药成功登陆港交所,迈进新的发展阶段。希望在资本市场的助力之下,亚盛医药早日将原创新药带给全球患者。



Related News / Recommended news More
2022 - 08 - 10
On August 9, the National Health Commission issued a notice, according to the approval opinions of the State Food and Drug Administration on the application for registration of additional indications for the treatment of novel coronavirus pneumonia with azvudine tablets. In order to further improve the antiviral treatment scheme for novel coronavirus pneumonia, the drug was included in the diagnos...
2022 - 08 - 05
Just recently, the Hong Kong Stock Exchange welcomed the successful submission of the first share of the new crown oral drug. On August 4, the Hong Kong Stock Exchange disclosed that Henan Zhenzhen Biotechnology Co., Ltd. (hereinafter referred to as 'Genuine Biotech') submitted a listing application to the Hong Kong Stock Exchange. Efung Capital is the only investment institution...
2022 - 08 - 01
Recently, Apexigen, a portfolio company of Efung Capital, and Brookline Capital Acquisition Corp.-a Special Purpose Acquisition Company (SPAC)-entered an official merger process, resulting that Brookline Capital Acquisition Corp. was renamed to Apexigen, Inc. Guided and led by Dr. Xiaodong Yang, president as well as Chief Executive Officer (CEO) of Apexigen company, the firm joined the listing of ...
2022 - 07 - 25
On July 25, 2022, the State Drug Administration proclaimed that, in accordance with the relevant provisions of the Drug Administration Law and specific drug approval procedures, the State Drug Administration conducted emergency review and approved Henan Zhenzhen Biotechnology Co., Ltd. with certain conditions. The registration application for Azvudine tablets to treat the novel coronavirus pneumon...
Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务